Clinical Study for Long QT Syndrome Types 2 & 3
Thryv Therapeutics Inc. is conducting a clinical study to evaluate the safety and tolerability of an investigational medicine, LQT-1213, in people with Long QT Syndrome Type 2 or Type 3.
We are looking for male and female participants between the ages 18-60 that have a diagnosis of Long QT Syndrome Type 2 or Type 3.
- 6-day commitment including travel time. Study will occur in a monitored clinical unit. We will work with your schedule to determine optimal timing.
- All participants in the study will be compensated a stipend for their time. All travel costs will be paid for as well as hotel and food costs for a companion.